StockData
Novartis AG logo

Novartis AG

NVSNYSEPharmaceutical PreparationsFiscal year ends December 31Also trades as NVSEF
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 20-F on Feb 4, 2026Score 7/30
$160.79−0.31 (-0.19%)

Close on Oct 30, 2026Market cap $306.81BP/E 22.5Yield –

Novartis Net Sales to Third Parties by Quarter

Net Sales to Third Parties ($M)

QuarterlyAnnual

Novartis Net Sales to Third Parties: $14,522M in Q3 2026, up 4.4% from a year earlier. That is the highest of the 36 quarters on record here.

Latest, Q3 2026
14,522
Period ended Sep 30, 2026
Change on a year earlier
+4.4%
13,909 in Q3 2025
History
36 quarters
Since Q4 2017
Sources
29
Documents cited below

Where the Q3 2026 figure comes from

“|| Total net sales to third parties | 14 522 | 13 909 | 4 | 4”

Source: Novartis Form 6-K (0001114448-26-000014) ↗

Novartis core revenue metric (Innovative Medicines continuing operations) is completely missing from the financial statements

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedNet Sales to Third Parties ($M)Year on yearSource
Q3 2026Sep 30, 202614,522+4.4%Novartis Form 6-K (0001114448-26-000014) ↗
Q2 2026Jun 30, 202614,408+2.5%Novartis Form 6-K (0001114448-26-000012) ↗
Q1 2026Mar 31, 202613,113-0.9%Novartis Form 6-K (0001114448-26-000010) ↗
Q4 2025Dec 31, 202513,336+1.4%Novartis Form 6-K (0001114448-26-000007) ↗
Q3 2025Sep 30, 202513,909+8.5%Novartis Form 6-K (0001114448-26-000014) ↗
Q2 2025Jun 30, 202514,054+12.3%Novartis Form 6-K (0001114448-26-000012) ↗
Q1 2025Mar 31, 202513,233+11.9%Novartis Form 6-K (0001114448-26-000010) ↗
Q4 2024Dec 31, 202413,153+15.1%Novartis Form 6-K (0001114448-26-000007) ↗
Q3 2024Sep 30, 202412,823+8.8%Novartis Form 6-K (0001114448-25-000003) ↗
Q2 2024Jun 30, 202412,512+9.4%Novartis Form 6-K (0001370368-25-000012) ↗
Q1 2024Mar 31, 202411,829+9.5%Novartis Form 6-K (0001370368-25-000010) ↗
Q4 2023Dec 31, 202311,423+8.0%Novartis Form 6-K (0001370368-25-000007) ↗
Q3 2023Sep 30, 202311,782+12.3%Novartis Form 6-K (0001370368-24-000022) ↗
Q2 2023Jun 30, 202311,437-10.5%Novartis Form 6-K (0001370368-24-000019) ↗
Q1 2023Mar 31, 202310,798-13.8%Novartis Form 6-K (0001370368-24-000017) ↗
Q4 2022Dec 31, 202210,576-20.1%Novartis Form 6-K (0001370368-24-000007) ↗

Breakdown

What makes up net Sales to Third Parties

Cite this data

StockData. (2026). Novartis Net Sales to Third Parties ($M), quarterly Q4 2017–Q3 2026 [Data set]. Compiled from Novartis SEC filings and investor materials. https://stockdatahq.com/stocks/nvs/kpis/core-net-sales-total

See every metric in the Novartis KPI table. Data updated Nov 2, 2026.